Cantor Fitzgerald Predicts CVRx FY2026 Earnings

CVRx, Inc. (NASDAQ:CVRX - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of CVRx in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn expects that the company will post earnings per share of ($1.49) for the year. The consensus estimate for CVRx's current full-year earnings is ($1.91) per share.

Several other research analysts also recently issued reports on the stock. Piper Sandler lowered their price target on shares of CVRx from $20.00 to $12.00 and set an "overweight" rating for the company in a report on Friday, May 9th. JPMorgan Chase & Co. reaffirmed an "underweight" rating and issued a $7.00 target price (down previously from $15.00) on shares of CVRx in a report on Friday, May 9th. Lake Street Capital cut their price target on CVRx from $19.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, April 8th. Finally, Canaccord Genuity Group reduced their price target on CVRx from $23.00 to $18.00 and set a "buy" rating on the stock in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $14.50.

CVRx Price Performance

CVRX stock traded up $0.29 during trading on Tuesday, reaching $6.52. 185,903 shares of the company were exchanged, compared to its average volume of 327,005. The company has a market capitalization of $170.00 million, a price-to-earnings ratio of -2.42 and a beta of 1.30. The company has a debt-to-equity ratio of 0.69, a current ratio of 12.06 and a quick ratio of 10.23. The company has a 50-day moving average of $6.90 and a two-hundred day moving average of $11.51. CVRx has a twelve month low of $4.30 and a twelve month high of $18.55.

CVRx (NASDAQ:CVRX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.03. CVRx had a negative return on equity of 93.06% and a negative net margin of 116.91%. The firm had revenue of $12.35 million during the quarter, compared to the consensus estimate of $14.68 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers boosted its position in CVRx by 13.0% during the first quarter. Rhumbline Advisers now owns 19,018 shares of the company's stock worth $233,000 after purchasing an additional 2,192 shares during the period. Parkman Healthcare Partners LLC raised its position in shares of CVRx by 33.5% in the first quarter. Parkman Healthcare Partners LLC now owns 1,229,522 shares of the company's stock valued at $15,037,000 after purchasing an additional 308,348 shares during the period. Cubist Systematic Strategies LLC lifted its stake in shares of CVRx by 48.1% during the 1st quarter. Cubist Systematic Strategies LLC now owns 59,105 shares of the company's stock valued at $723,000 after buying an additional 19,183 shares in the last quarter. AlphaQuest LLC boosted its holdings in CVRx by 725.4% in the 1st quarter. AlphaQuest LLC now owns 6,108 shares of the company's stock worth $75,000 after buying an additional 5,368 shares during the period. Finally, Lord Abbett & CO. LLC purchased a new position in CVRx in the 1st quarter valued at approximately $4,852,000. Institutional investors own 75.27% of the company's stock.

Insider Activity

In other news, Director Kirk G. Nielsen bought 10,966 shares of the firm's stock in a transaction on Thursday, May 15th. The stock was acquired at an average cost of $5.45 per share, with a total value of $59,764.70. Following the completion of the transaction, the director now directly owns 1,910,134 shares of the company's stock, valued at $10,410,230.30. This represents a 0.58% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders purchased 78,666 shares of company stock valued at $411,031 in the last three months. Company insiders own 13.90% of the company's stock.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.